

## NORWOOD ABBEY AND NORWOOD IMMUNOLOGY HALF YEAR REPORTS

Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that Norwood Immunology Ltd's ("NIM") half year report has been lodged and is posted on the NIM website.

NIM has reported a substantial profit, flowing from the sale of its interest in Bestiwill Holdings and Virosome Biologicals. As previously advised, NIM has also declared and paid a special dividend of one pence per share.

NIM also reports that it is reviewing its future strategy, following disappointing results from the thymus clinical trials. The NIM Board states that costs are being minimized and that delisting from AIM is an option being considered to further reduce costs, especially given that the AIM listing has not provided any degree of liquidity for the company's shares.

NIM's main asset is the A\$5 million (approx) three-year 5% convertible note held in Mymetics Inc. plus further significant conditional potential returns from milestone payments associated with the Virosome project.

NIM is also progressing its therapeutic stem cell treatments, currently involving veterinary trials, which have yielded encouraging results.

The NIM Board has indicated that a further update will be provided in the near future.

As a result of the payment of the NIM dividend and the clarification of the ongoing NIM business plan, Norwood Abbey is progressing its half year report and anticipates completion and release during June at which time the company will seek to reinstate the quotation of its securities on the ASX.